Get the Stockscreener App
0.3861
35.89%
-0.2161
Lakewood Amedex Biotherapeutics Inc stock is traded at $0.3861, with a volume of 1.81M.
It is down -35.89% in the last 24 hours and down -59.37% over the past month.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
See More
Previous Close:
$0.6022
Open:
$0.563
24h Volume:
1.81M
Relative Volume:
1.13
Market Cap:
$6.76M
Revenue:
-
Net Income/Loss:
$-4.23M
P/E Ratio:
-0.4388
EPS:
-0.88
Net Cash Flow:
$-1.89M
1W Performance:
-46.58%
1M Performance:
-59.37%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.366
$0.5895
1-Week Range:
$0.366
$0.7741
52-Week Range:
$0.366
$9.40
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Company Profile
Name
Lakewood Amedex Biotherapeutics Inc
Sector
Industry
Phone
(941) 225-2515
Address
8031 COOPER CREEK BLVD., UNIVERSITY PARK
Compare LABT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LABT
Lakewood Amedex Biotherapeutics Inc
|
0.3861 | 6.76M | 0 | -4.23M | -1.89M | -0.88 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Latest News
Lakewood-Amedex Biotherapeutics plans 1-for-10 reverse stock split - Investing.com
Lakewood-Amedex (NASDAQ: LABT) plans 1-for-10 reverse stock split - Stock Titan
LABT Stock Soars 50% After Nasdaq Debut – Retail Says $14 Is The Line In The Sand - Stocktwits
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - PR Newswire
Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
Lakewood-Amedex Biotherapeutics (LABT) Stock Price, News & Analysis $LABT - MarketBeat
Lakewood-Amedex Biotherapeutics (LABT) Stock Trends and Sentiment 2026 $LABT - MarketBeat
Lakewood-Amedex stock falls despite positive Nu-3 manufacturing update - MSN
Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper - TipRanks
Lakewood-Amedex Biotherapeutics(LABT) Stock Options Chain | Quotes & News - Moomoo
Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial - Investing.com Nigeria
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers - GuruFocus
Lakewood-Amedex Biotherapeutics issued two new patents - TipRanks
Lakewood-Amedex receives patents in Australia, New Zealand By Investing.com - Investing.com South Africa
Lakewood-Amedex receives patents in Australia, New Zealand - Investing.com Australia
Lakewood-Amedex (LABT) posts Q1 loss, closes Series C for ~$7.5M - Stock Titan
LABT - Finviz
Lakewood-Amedex (LABT) registers 9,375,000 shares after $7.5M Series C raise - Stock Titan
Lakewood-Amedex Biotherapeutics Inc. Reports Q1 2026 Financial Results and Advances in Antimicrobial Therapy Development - minichart.com.sg
Lakewood-Amedex Biotherapeutics Inc. 1Q 2026: Revenue ($886.75K), EPS ($0.2) — 10-Q Summary - TradingView
Lakewood-Amedex (LABT) logs $0.9M loss, raises $7.5M and still faces going concern risk - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) AI-Powered Stock Analysis - Meyka
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers - Sahm
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update - Sahm
Lakewood-Amedex Biotherapeutics advances production of foot ulcer candidate Nu3 - TipRanks
Positive Nu-3 Data Advances Lakewood-Amedex Toward Phase 2 Diabetic Foot Ulcer Trial (LABT) - Yahoo Finance
Lakewood-Amedex completes manufacturing steps for Nu-3 trial By Investing.com - Investing.com South Africa
LABT Stock Slides As Volatility Grips Biotech Micro-Cap - StocksToTrade
Lakewood-Amedex Provides Progress Update Of Nu-3 In Diabetic Foot Ulcers; Stock Down - RTTNews
Lakewood-Amedex Biotherapeutics Announces Positive Data For The Advancement Of Lead Candidate, Nu-3 - TradingView
LABT Stock Slides As Volatility Tests Biotech Day Traders - timothysykes.com
Lakewood-Amedex completes manufacturing steps for Nu-3 trial - Investing.com
Lakewood-Amedex jumps 20% in Nasdaq market debut - MSN
LABT Should I Buy - Intellectia AI
Lakewood‑Amedex (LABT) registers 9.65M shares tied to Series C conversion - Stock Titan
[EFFECT] Lakewood-Amedex Biotherapeutics Inc. SEC Filing - Stock Titan
LABT Stock Price, Quote & Chart | LAKEWOOD-AMEDEX BIOTHERAPEUT (NASDAQ:LABT) - ChartMill
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to - GuruFocus
Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial By Investing.com - Investing.com South Africa
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):